Quantum SI

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Quantum SI headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Diagnostics sector. The company focuses on Biotechnology and has secured $10.2B in funding across 24 round(s). With a team of 101-250 employees, Quantum SI is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Quantum SI, raised $425.0M. Discover more about their projects, partnerships, and impact on our platform.